EGFR Tyrosine Kinase Inhibitors Epigenetics Immunotherapy CD Protein Inhibitors Immune Checkpoint Inhibitors PARP Inhibitors BCL Inhibitors Cyclin Dependent Kinase Inhibitors Serine-Threonine Kinase Inhibitors MDM2/MDMX Other | Non Small Cell Lung Cancer | Small Cell Lung Cancer | Ovarian Cancer | Esophageal Cancer | Melanoma | Acute Myelogenous Leukemia | Solid Tumor | Triple Negative Breast Cancer | HER2 Positive Breast Cancer | Squamous Cell Carcinoma of Head and Neck | Hepatocellular Cancer | Estrogen Receptor Positive Breast Cancer | Pancreatic Cancer | Prostate Cancer | Medulloblastoma | Colon Cancer | Gastric Cancer | Head and Neck Cancer |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
gefitinib | ||||||||||||||||||
AZD1775 | ||||||||||||||||||
ibrutinib | ||||||||||||||||||
venetoclax | ||||||||||||||||||
bevacizumab | ||||||||||||||||||
trastuzumab + atezolizumab + pertuzumab | ||||||||||||||||||
nivolumab | ||||||||||||||||||
talazoparib + GSK525762 | ||||||||||||||||||
YPN-005 | ||||||||||||||||||
ACR-368 | ||||||||||||||||||
PCM-075 | ||||||||||||||||||
APR-246 | ||||||||||||||||||
KB-0742 | ||||||||||||||||||
RMC-5552 | ||||||||||||||||||
Immunotherapy | ||||||||||||||||||
durvalumab | ||||||||||||||||||
talazoparib | ||||||||||||||||||
osimertinib |